Ianalumab: A Breakthrough Treatment for Sjögren’s Disease
Sjögren’s disease is a chronic autoimmune disorder affecting moisture-producing glands, leading to dry eyes, dry mouth, fatigue, and joint pain. It is the second most common rheumatic autoimmune disease, yet it remains underdiagnosed and difficult to manage due to its diverse symptoms. Approximately 0.25 percent of the global population is affected, with nearly half of the cases undiagnosed. Effective treatment options are critically needed to improve the quality of life for patients.
Recent advancements in immunology have introduced ianalumab, a fully human monoclonal antibody that targets B-cells. B-cells are responsible for producing autoantibodies that attack healthy tissue. Ianalumab uses a dual mechanism to deplete B-cells and inhibit their activation and survival via BAFF-R blockade. This targeted therapy addresses the underlying immune dysregulation in Sjögren’s disease and offers a promising option for patients who have limited treatment choices.
The U.S. Food and Drug Administration (FDA) granted ianalumab Breakthrough Therapy designation, recognizing its potential to treat serious conditions and meet unmet medical needs. This designation was based on positive results from multiple studies, including Phase III trials, which demonstrated meaningful improvements in disease activity and patient burden.
The Phase III clinical trials, NEPTUNUS-1 and NEPTUNUS-2, evaluated ianalumab in patients with Sjögren’s disease. Both trials were global, multicenter, randomized, and double-blind. Results showed that ianalumab significantly improved disease activity scores while maintaining a safety profile similar to placebo. Patients reported reduced fatigue, dryness, and pain, addressing the core symptoms of Sjögren’s disease.
Sjögren’s disease often involves systemic complications beyond the exocrine glands, including fatigue, joint pain, and increased lymphoma risk. These complications significantly affect physical and emotional well-being. Traditional treatments primarily focus on symptom relief, such as artificial tears for dry eyes and saliva substitutes for dry mouth, without targeting the immune mechanisms causing the disease. Ianalumab offers a disease-modifying approach that may change the course of Sjögren’s disease and improve long-term outcomes.
Ianalumab’s mechanism of action involves BAFF-R inhibition, which prevents survival signals for B-cells and selectively depletes autoreactive cells. This reduces harmful autoantibody production and helps restore immune balance. Its dual approach ensures precision, minimizes off-target effects, and enhances safety.
The development of ianalumab represents a step forward in personalized medicine. Sjögren’s disease varies among patients, with differences in symptom severity, organ involvement, and disease progression. Targeted therapy like ianalumab provides a personalized treatment option that addresses the molecular cause of the disease, aligning with modern trends in immunology.
Regulatory support, such as Breakthrough Therapy designation, accelerates the development and review of promising therapies. Novartis plans to submit ianalumab for global approval in early 2026. If approved, it would become the first targeted treatment for Sjögren’s disease, offering a transformative impact on patient care.
The disease burden for Sjögren’s patients extends beyond physical symptoms. Chronic fatigue, persistent dryness, and joint pain impair daily life and contribute to emotional distress. Ianalumab’s improvements in disease activity and symptom management suggest it can help reduce both physical and psychosocial burdens.
Ianalumab’s development demonstrates advances in autoimmune disease management through targeted B-cell modulation. It provides a model for applying immunotherapy to systemic autoimmune conditions and offers insights for treating other B-cell mediated disorders, such as lupus and rheumatoid arthritis.
Safety is a key consideration for chronic therapy. NEPTUNUS-1 and NEPTUNUS-2 trials showed that adverse events and serious adverse events were similar to placebo. Maintaining a low risk of complications is important for long-term treatment adherence and patient confidence.
Collaboration between pharmaceutical companies, regulatory agencies, and healthcare providers is essential for bringing therapies like ianalumab to patients. Success relies on rigorous trials, careful monitoring, and transparent communication. Positive trial outcomes reflect both scientific innovation and patient-centered research.
Ianalumab has the potential to redefine the standard of care for Sjögren’s disease. Existing treatments focus on symptom relief, while ianalumab addresses underlying immune dysfunction. This targeted therapy may slow disease progression, improve symptom management, and enhance quality of life for patients who previously had few options.
In conclusion, ianalumab is a significant advancement in Sjögren’s disease treatment. Its dual mechanism targets B-cells, providing a novel approach to a complex autoimmune disorder. Clinical trials show efficacy and safety, offering hope for patients with limited options. FDA Breakthrough Therapy designation emphasizes its potential to meet unmet medical needs. As Novartis prepares for regulatory submission, ianalumab may transform care for patients with Sjögren’s disease.
For more information on ianalumab and clinical updates, visit Novartis and trusted medical sources such as Drugs.com. This therapy represents the future of personalized immunology, where targeted interventions improve outcomes and redefine autoimmune disease management.
Disclaimer: This blog is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a healthcare professional for guidance regarding any medical condition or therapy.
References:
- Grader-Beck T, et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s Disease: Efficacy and safety results from NEPTUNUS-1 and NEPTUNUS-2. American College of Rheumatology Congress; October 2025; Chicago, Illinois.
- National Academies of Sciences, Engineering, and Medicine. Sjögren’s Disease/Syndrome. [Accessed December 2025]
- Dorner T, et al. Safety and efficacy of ianalumab in patients with Sjögren’s disease: Phase 2b study. Arthritis Rheumatol. 2025;77(5):560–570.
- U.S. Food and Drug Administration. Breakthrough therapy. [Accessed December 2025]
- Negrini S, et al. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9–25.
- Mariette X, Criswell LA. Primary Sjögren’s symptoms. N Engl J Med. 2018;378:931–939.
- Gairy K, et al. Burden of illness among patients with primary Sjögren’s syndrome and systemic involvement. Rheumatology. 2021;60(4):1871–1881.
- Conrad N, et al. Incidence and prevalence of autoimmune disorders in the UK. Lancet. 2023;401(10391):1878–1890.
- Narváez J, et al. Prevalence of Sjögren’s syndrome in Spain: estimating undiagnosed cases. Sci Rep. 2020;10(1):10627.
- ClinicalTrials.gov NCT05350072 [Accessed December 2025].
- ClinicalTrials.gov NCT0539214 [Accessed December 2025].
- Novartis. Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease. Drugs.com. January 16, 2026.